Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Notice To Readers: FDA Approval of
VAQTA® (Hepatitis A Vaccine, Inactivated) for Children Aged
>1 Year
On August 11, 2005, the Food and Drug Administration (FDA) approved an application of a
pediatric/adolescent formulation of
VAQTA® (hepatitis A vaccine, inactivated) (Merck & Co., Whitehouse Station, New Jersey) for use
among persons aged 12 months--18 years. Previously, the pediatric/adolescent formulation of VAQTA was approved for use
in persons aged 2--18 years. The approved labeling change
applies only to VAQTA and not to other licensed hepatitis A vaccines.
The formulation, dosage, and schedule for VAQTA have not changed. Each 0.5 mL dose of the
pediatric/adolescent formulation of VAQTA contains approximately 25 units of formalin-inactivated hepatitis A virus antigen, adsorbed
onto aluminum hydroxyphosphate sulfate, in 0.9% sodium chloride. The formulation does not contain a preservative.
VAQTA is now indicated for active immunization of persons aged
>12 months to protect against disease caused by
hepatitis A virus. The primary vaccination schedule is
unchanged and consists of 2 doses, administered on a 0, 6--18 month
schedule. The Advisory Committee on Immunization Practices (ACIP) has issued recommendations for hepatitis A vaccination
(1).
Results from the study to lower the age indication for VAQTA indicated that 100% of 343 initially seronegative
children aged 12--23 months who received 2 doses of VAQTA had seroconverted to antibody levels previously indicated to
be protective. The study also indicated that VAQTA may be
administered concomitantly with M-M-R II (measles, mumps,
and rubella virus vaccine live). Insufficient data are available to evaluate the concomitant use of VAQTA with other
routinely recommended childhood vaccines. According to the general recommendations of ACIP, inactivated vaccines generally do
not interfere with the immune response to other inactivated or live vaccines
(2).
In combined clinical trials reported as part of the labeling change application, 706 healthy children aged 12--23
months received >1 doses of VAQTA alone or in combination with other routinely recommended pediatric vaccines. The
most commonly reported complaints after 1 or both doses of VAQTA were similar to those reported among older children
(1). VAQTA is contraindicated in persons with known hypersensitivity to any component of the vaccine.
Additional information is available from the manufacturer's package insert and at telephone 800-672-6372.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
